IDH2 and cholangiocarcinoma: IDH2 mutation was most common in acute myeloid leukemia (11%), followed by <6% in cholangiocarcinoma; however, IDH2 amplification was more common, albeit at low frequencies, among various cancer types (Figure 2B).